{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T18:08:32Z","timestamp":1793383712917,"version":"4.5.0"},"reference-count":143,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T00:00:00Z","timestamp":1747440000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T00:00:00Z","timestamp":1747440000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005187","name":"University of Athens","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005187","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>Uveal melanoma (UM) is the most common intraocular malignancy in adults, representing a rare but aggressive melanoma subtype with a distinct molecular landscape, unique metastatic behavior and limited therapeutic options in the metastatic setting. This review provides an in-depth analysis of the latest evidence on the evolving treatment landscape of metastatic UM.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>For liver-only metastatic disease, locoregional therapies provide significant benefit compared to systemic therapies. The recent approval of tebentafusp-tebn, a bispecific gp100 peptide-HLA-directed CD3 T-cell engager, marks a pivotal advancement for HLA-A*02:01-positive patients with unresectable\/metastatic UM, demonstrating a clinically significant survival benefit. Several clinical studies are currently active, examining emerging locoregional and systemic treatments for metastatic UM, with promising early data.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Despite effective local disease control through radiotherapy and enucleation, approximately 50% of patients develop metastatic disease, predominantly in the liver, with a median survival of less than one year. The approval of tebentafusp represents a landmark achievement in UM treatment, while promising experimental combinations have demonstrated clinical utility in late phase clinical trials, offering hope for further improvement in patient survival.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s11912-025-01684-0","type":"journal-article","created":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T22:17:57Z","timestamp":1747433877000},"page":"803-821","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["State-of-the-art in Metastatic Uveal Melanoma Treatment: A 2025 Update"],"prefix":"10.1007","volume":"27","author":[{"given":"Dimitrios C.","family":"Ziogas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitra","family":"Foteinou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charalampos","family":"Theocharopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasios","family":"Martinos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dioni-Pinelopi","family":"Petsiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amalia","family":"Anastasopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Gogas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,17]]},"reference":[{"key":"1684_CR1","doi-asserted-by":"publisher","unstructured":"Chang AE. Karnell LH. Menck HR. The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer 1998;83: 1664\u20131678. https:\/\/doi.org\/10.1002\/(sici)1097-0142(19981015)83:8<1664::aid-cncr23>3.0.co;2-g.","DOI":"10.1002\/(sici)1097-0142(19981015)83:8<1664::aid-cncr23>3.0.co;2-g"},{"key":"1684_CR2","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1001\/archophthalmol.2009.208","volume":"127","author":"CL Shields","year":"2009","unstructured":"Shields CL, Furuta M, Thangappan A, Nagori S, Mashayekhi A, Lally DR, Kelly CC, Rudich DS, Nagori AV, Wakade OA, et al. Metastasis of uveal melanoma millimeter-by-millimeter in 8033 consecutive eyes. Arch Ophthalmol. 2009;127:989\u201398. https:\/\/doi.org\/10.1001\/archophthalmol.2009.208.","journal-title":"Arch Ophthalmol"},{"key":"1684_CR3","doi-asserted-by":"publisher","unstructured":"Silva-Rodriguez P. Fernandez-Diaz D. Bande M. Pardo M. Loidi L. Blanco-Teijeiro MJ. GNAQ and GNA11 Genes: A Comprehensive Review on Oncogenesis, Prognosis and Therapeutic Opportunities in Uveal Melanoma. Cancers (Basel) 2022;14\u00a0https:\/\/doi.org\/10.3390\/cancers14133066.","DOI":"10.3390\/cancers14133066"},{"key":"1684_CR4","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1097\/COC.0b013e3182546a6b","volume":"36","author":"NA Kolandjian","year":"2013","unstructured":"Kolandjian NA, Wei C, Patel SP, Richard JL, Dett T, Papadopoulos NE, Bedikian AY. Delayed systemic recurrence of uveal melanoma. Am J Clin Oncol. 2013;36:443\u20139. https:\/\/doi.org\/10.1097\/COC.0b013e3182546a6b.","journal-title":"Am J Clin Oncol"},{"key":"1684_CR5","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1038\/s41416-022-01723-8","volume":"126","author":"AB Beasley","year":"2022","unstructured":"Beasley AB, Chen FK, Isaacs TW, Gray ES. Future perspectives of uveal melanoma blood based biomarkers. Br J Cancer. 2022;126:1511\u201328. https:\/\/doi.org\/10.1038\/s41416-022-01723-8.","journal-title":"Br J Cancer"},{"key":"1684_CR6","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1093\/annonc\/mdz176","volume":"30","author":"L Khoja","year":"2019","unstructured":"Khoja L, Atenafu EG, Suciu S, Leyvraz S, Sato T, Marshall E, Keilholz U, Zimmer L, Patel SP, Piperno-Neumann S, et al. Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study. Ann Oncol. 2019;30:1370\u201380. https:\/\/doi.org\/10.1093\/annonc\/mdz176.","journal-title":"Ann Oncol"},{"key":"1684_CR7","doi-asserted-by":"publisher","unstructured":"Collaborative Ocular Melanoma Study, G. Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in the Collaborative Ocular Melanoma Study (COMS): COMS report no. 15. Arch Ophthalmol 2001;119:670\u2013676, https:\/\/doi.org\/10.1001\/archopht.119.5.670.","DOI":"10.1001\/archopht.119.5.670"},{"key":"1684_CR8","doi-asserted-by":"publisher","first-page":"e147","DOI":"10.1634\/theoncologist.2019-0244","volume":"25","author":"SJ Klempner","year":"2020","unstructured":"Klempner SJ, Fabrizio D, Bane S, Reinhart M, Peoples T, Ali SM, Sokol ES, Frampton G, Schrock AB, Anhorn R, et al. Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current Evidence. Oncologist. 2020;25:e147\u201359. https:\/\/doi.org\/10.1634\/theoncologist.2019-0244.","journal-title":"Oncologist"},{"key":"1684_CR9","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/nri.2017.131","volume":"18","author":"Z Hu","year":"2018","unstructured":"Hu Z, Ott PA, Wu CJ. Towards personalized, tumour-specific, therapeutic vaccines for cancer. Nat Rev Immunol. 2018;18:168\u201382. https:\/\/doi.org\/10.1038\/nri.2017.131.","journal-title":"Nat Rev Immunol"},{"key":"1684_CR10","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.annonc.2021.02.006","volume":"32","author":"DJ McGrail","year":"2021","unstructured":"McGrail DJ, Pilie PG, Rashid NU, Voorwerk L, Slagter M, Kok M, Jonasch E, Khasraw M, Heimberger AB, Lim B, et al. High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types. Ann Oncol. 2021;32:661\u201372. https:\/\/doi.org\/10.1016\/j.annonc.2021.02.006.","journal-title":"Ann Oncol"},{"key":"1684_CR11","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13073-017-0424-2","volume":"9","author":"ZR Chalmers","year":"2017","unstructured":"Chalmers ZR, Connelly CF, Fabrizio D, Gay L, Ali SM, Ennis R, Schrock A, Campbell B, Shlien A, Chmielecki J, et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 2017;9:34. https:\/\/doi.org\/10.1186\/s13073-017-0424-2.","journal-title":"Genome Med"},{"key":"1684_CR12","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s42764-020-00009-8","volume":"1","author":"GP Pfeifer","year":"2020","unstructured":"Pfeifer GP. Mechanisms of UV-induced mutations and skin cancer. Genome Instab Dis. 2020;1:99\u2013113. https:\/\/doi.org\/10.1007\/s42764-020-00009-8.","journal-title":"Genome Instab Dis"},{"key":"1684_CR13","doi-asserted-by":"publisher","unstructured":"Dousset L. Poizeau F. Robert C. Mansard S. Mortier L. Caumont C. Routier \u00c9. Dupuy A. Rouanet J. Battistella M. et al. Positive Association Between Location of Melanoma, Ultraviolet Signature, Tumor Mutational Burden, and Response to Anti\u2013PD-1 Therapy. JCO Prec Onco\u00a02021;1821\u20131829, https:\/\/doi.org\/10.1200\/po.21.00084.","DOI":"10.1200\/po.21.00084"},{"key":"1684_CR14","doi-asserted-by":"publisher","unstructured":"Hilke FJ. Sinnberg T. Gschwind A. Niessner H. Demidov G. Amaral T. Ossowski S. Bonzheim, I. Rocken M. Riess O et al. Distinct Mutation Patterns Reveal Melanoma Subtypes and Influence Immunotherapy Response in Advanced Melanoma Patients. Cancers (Basel) 2020;12\u00a0https:\/\/doi.org\/10.3390\/cancers12092359.","DOI":"10.3390\/cancers12092359"},{"key":"1684_CR15","unstructured":"Mobuchon L. Battistella A. Bardel C. Scelo G. Renoud A. Houy A. Cassoux N. Milder M. Cancel-Tassin G. Cussenot O. et al. A GWAS in uveal melanoma identifies risk polymorphisms in the CLPTM1L locus."},{"key":"1684_CR16","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1136\/jmedgenet-2011-100156","volume":"48","author":"MH Abdel-Rahman","year":"2011","unstructured":"Abdel-Rahman MH, Pilarski R, Cebulla CM, Massengill JB, Christopher BN, Boru G, Hovland P, Davidorf FH. Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers. J Med Genet. 2011;48:856\u20139. https:\/\/doi.org\/10.1136\/jmedgenet-2011-100156.","journal-title":"J Med Genet"},{"key":"1684_CR17","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1002\/gcc.22424","volume":"56","author":"K Rai","year":"2017","unstructured":"Rai K, Pilarski R, Boru G, Rehman M, Saqr AH, Massengill JB, Singh A, Marino MJ, Davidorf FH, Cebulla CM, et al. Germline BAP1 alterations in familial uveal melanoma. Genes Chromosomes Cancer. 2017;56:168\u201374. https:\/\/doi.org\/10.1002\/gcc.22424.","journal-title":"Genes Chromosomes Cancer"},{"key":"1684_CR18","doi-asserted-by":"publisher","first-page":"175883592096585","DOI":"10.1177\/1758835920965852","volume":"12","author":"Y Li","year":"2020","unstructured":"Li Y, Shi J, Yang J, Ge S, Zhang J, Jia R, Fan X. Uveal melanoma: progress in molecular biology and therapeutics. Ther Adv Med Oncol. 2020;12:1758835920965852. https:\/\/doi.org\/10.1177\/1758835920965852.","journal-title":"Ther Adv Med Oncol"},{"key":"1684_CR19","doi-asserted-by":"publisher","first-page":"S60","DOI":"10.21037\/tlcr.2019.11.24","volume":"9","author":"DA Kobrinski","year":"2020","unstructured":"Kobrinski DA, Yang H, Kittaneh M. BAP1: role in carcinogenesis and clinical implications. Transl Lung Cancer Res. 2020;9:S60\u20136. https:\/\/doi.org\/10.21037\/tlcr.2019.11.24.","journal-title":"Transl Lung Cancer Res"},{"key":"1684_CR20","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1038\/modpathol.2014.43","volume":"27","author":"AE Koopmans","year":"2014","unstructured":"Koopmans AE, Verdijk RM, Brouwer RW, van den Bosch TP, van den Berg MM, Vaarwater J, Kockx CE, Paridaens D, Naus NC, Nellist M, et al. Clinical significance of immunohistochemistry for detection of BAP1 mutations in uveal melanoma. Mod Pathol. 2014;27:1321\u201330. https:\/\/doi.org\/10.1038\/modpathol.2014.43.","journal-title":"Mod Pathol"},{"key":"1684_CR21","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1038\/ng.2674","volume":"45","author":"M Martin","year":"2013","unstructured":"Martin M, Masshofer L, Temming P, Rahmann S, Metz C, Bornfeld N, van de Nes J, Klein-Hitpass L, Hinnebusch AG, Horsthemke B, et al. Exome sequencing identifies recurrent somatic mutations in EIF1AX and SF3B1 in uveal melanoma with disomy 3. Nat Genet. 2013;45:933\u20136. https:\/\/doi.org\/10.1038\/ng.2674.","journal-title":"Nat Genet"},{"key":"1684_CR22","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1158\/2159-8290.CD-13-0330","volume":"3","author":"SJ Furney","year":"2013","unstructured":"Furney SJ, Pedersen M, Gentien D, Dumont AG, Rapinat A, Desjardins L, Turajlic S, Piperno-Neumann S, de la Grange P, Roman-Roman S, et al. SF3B1 mutations are associated with alternative splicing in uveal melanoma. Cancer Discov. 2013;3:1122\u20139. https:\/\/doi.org\/10.1158\/2159-8290.CD-13-0330.","journal-title":"Cancer Discov"},{"key":"1684_CR23","doi-asserted-by":"publisher","unstructured":"Yavuzyigitoglu, S.; Koopmans, A.E.; Verdijk, R.M.; Vaarwater, J.; Eussen, B.; van Bodegom, A.; Paridaens, D.; Kilic, E.; de Klein, A.; Rotterdam Ocular Melanoma Study, G. Uveal Melanomas with SF3B1 Mutations: A Distinct Subclass Associated with Late-Onset Metastases. Ophthalmology 2016, 123, 1118\u20131128, https:\/\/doi.org\/10.1016\/j.ophtha.2016.01.023.","DOI":"10.1016\/j.ophtha.2016.01.023"},{"key":"1684_CR24","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1093\/jnci\/djab167","volume":"114","author":"L Mobuchon","year":"2022","unstructured":"Mobuchon L, Derrien AC, Houy A, Verrier T, Pierron G, Cassoux N, Milder M, Deleuze JF, Boland A, Scelo G, et al. Different Pigmentation Risk Loci for High-Risk Monosomy 3 and Low-Risk Disomy 3 Uveal Melanomas. J Natl Cancer Inst. 2022;114:302\u20139. https:\/\/doi.org\/10.1093\/jnci\/djab167.","journal-title":"J Natl Cancer Inst"},{"key":"1684_CR25","doi-asserted-by":"publisher","first-page":"5721","DOI":"10.1167\/iovs.13-12195","volume":"54","author":"KG Ewens","year":"2013","unstructured":"Ewens KG, Kanetsky PA, Richards-Yutz J, Al-Dahmash S, De Luca MC, Bianciotto CG, Shields CL, Ganguly A. Genomic profile of 320 uveal melanoma cases: chromosome 8p-loss and metastatic outcome. Invest Ophthalmol Vis Sci. 2013;54:5721\u20139. https:\/\/doi.org\/10.1167\/iovs.13-12195.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1684_CR26","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1016\/S0140-6736(96)90736-9","volume":"347","author":"N Bornfeld","year":"1996","unstructured":"Bornfeld N, Prescher G, Becher R, Hirche H, J\u00f6ckel KH, Horsthemke B. Prognostic implications of monosomy 3 in uveal melanoma. The Lancet. 1996;347:1222\u20135. https:\/\/doi.org\/10.1016\/S0140-6736(96)90736-9.","journal-title":"The Lancet"},{"key":"1684_CR27","doi-asserted-by":"publisher","first-page":"93","DOI":"10.4103\/0301-4738.154367","volume":"63","author":"S Kaliki","year":"2015","unstructured":"Kaliki S, Shields CL, Shields JA. Uveal melanoma: estimating prognosis. Indian J Ophthalmol. 2015;63:93\u2013102. https:\/\/doi.org\/10.4103\/0301-4738.154367.","journal-title":"Indian J Ophthalmol"},{"key":"1684_CR28","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/eye.2016.275","volume":"31","author":"S Kaliki","year":"2017","unstructured":"Kaliki S, Shields CL. Uveal melanoma: relatively rare but deadly cancer. Eye (Lond). 2017;31:241\u201357. https:\/\/doi.org\/10.1038\/eye.2016.275.","journal-title":"Eye (Lond)"},{"key":"1684_CR29","doi-asserted-by":"publisher","first-page":"7205","DOI":"10.1158\/0008-5472.CAN-04-1750","volume":"64","author":"MD Onken","year":"2004","unstructured":"Onken MD, Worley LA, Ehlers JP, Harbour JW. Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death. Cancer Res. 2004;64:7205\u20139. https:\/\/doi.org\/10.1158\/0008-5472.CAN-04-1750.","journal-title":"Cancer Res"},{"key":"1684_CR30","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1016\/j.ophtha.2012.02.017","volume":"119","author":"MD Onken","year":"2012","unstructured":"Onken MD, Worley LA, Char DH, Augsburger JJ, Correa ZM, Nudleman E, Aaberg TM Jr, Altaweel MM, Bardenstein DS, Finger PT, et al. Collaborative Ocular Oncology Group report number 1: prospective validation of a multi-gene prognostic assay in uveal melanoma. Ophthalmology. 2012;119:1596\u2013603. https:\/\/doi.org\/10.1016\/j.ophtha.2012.02.017.","journal-title":"Ophthalmology"},{"key":"1684_CR31","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1001\/archopht.1977.04450010050004","volume":"95","author":"MJ McLean","year":"1977","unstructured":"McLean MJ, Foster WD, Zimmerman LE. Prognostic factors in small malignant melanomas of choroid and ciliary body. Arch Ophthalmol. 1977;95:48\u201358. https:\/\/doi.org\/10.1001\/archopht.1977.04450010050004.","journal-title":"Arch Ophthalmol"},{"key":"1684_CR32","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1167\/iovs.65.2.11","volume":"65","author":"DP de Bruyn","year":"2024","unstructured":"de Bruyn DP, van Poppelen NM, Brands T, van den Boom SC, Eikenboom E, Wagner A, van Veghel-Plandsoen MM, Geeven G, Beverloo B, van Rij CM, et al. Evaluation of Circulating Tumor DNA as a Liquid Biomarker in Uveal Melanoma. Invest Ophthalmol Vis Sci. 2024;65:11. https:\/\/doi.org\/10.1167\/iovs.65.2.11.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1684_CR33","doi-asserted-by":"publisher","first-page":"2364","DOI":"10.1038\/s41591-022-02015-7","volume":"28","author":"RD Carvajal","year":"2022","unstructured":"Carvajal RD, Butler MO, Shoushtari AN, Hassel JC, Ikeguchi A, Hernandez-Aya L, Nathan P, Hamid O, Piulats JM, Rioth M, et al. Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial. Nat Med. 2022;28:2364\u201373. https:\/\/doi.org\/10.1038\/s41591-022-02015-7.","journal-title":"Nat Med"},{"key":"1684_CR34","doi-asserted-by":"publisher","first-page":"8851","DOI":"10.1038\/s41467-024-53145-0","volume":"15","author":"M Rodrigues","year":"2024","unstructured":"Rodrigues M, Ramtohul T, Rampanou A, Sandoval JL, Houy A, Servois V, Mailly-Giacchetti L, Pierron G, Vincent-Salomon A, Cassoux N, et al. Prospective assessment of circulating tumor DNA in patients with metastatic uveal melanoma treated with tebentafusp. Nat Commun. 2024;15:8851. https:\/\/doi.org\/10.1038\/s41467-024-53145-0.","journal-title":"Nat Commun"},{"key":"1684_CR35","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1167\/iovs.16-20212","volume":"58","author":"M Dogrus\u00f6z","year":"2017","unstructured":"Dogrus\u00f6z M, Bagger M, van Duinen SG, Kroes WG, Ruivenkamp CA, B\u00f6hringer S, Andersen KK, Luyten GP, Kiilgaard JF, Jager MJ. The Prognostic Value of AJCC Staging in Uveal Melanoma Is Enhanced by Adding Chromosome 3 and 8q Status. Invest Ophthalmol Vis Sci. 2017;58:833\u201342. https:\/\/doi.org\/10.1167\/iovs.16-20212.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1684_CR36","doi-asserted-by":"publisher","first-page":"308","DOI":"10.4103\/sjopt.sjopt_69_21","volume":"36","author":"CL Shields","year":"2022","unstructured":"Shields CL, Dockery PW, Mayro EL, Bas Z, Yaghy A, Lally SE, Orloff M, Sato T, Shields JA. Conditional survival of uveal melanoma using The Cancer Genome Atlas (TCGA) classification (Simplified Version) in 1001 cases. Saudi J Ophthalmol. 2022;36:308\u201314. https:\/\/doi.org\/10.4103\/sjopt.sjopt_69_21.","journal-title":"Saudi J Ophthalmol"},{"key":"1684_CR37","doi-asserted-by":"publisher","first-page":"6116","DOI":"10.1167\/iovs.16-19654","volume":"57","author":"SW DeParis","year":"2016","unstructured":"DeParis SW, Taktak A, Eleuteri A, Enanoria W, Heimann H, Coupland SE, Damato B. External Validation of the Liverpool Uveal Melanoma Prognosticator Online. Invest Ophthalmol Vis Sci. 2016;57:6116\u201322. https:\/\/doi.org\/10.1167\/iovs.16-19654.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1684_CR38","doi-asserted-by":"publisher","first-page":"4096","DOI":"10.1167\/iovs.17-22255","volume":"58","author":"J Vaquero-Garcia","year":"2017","unstructured":"Vaquero-Garcia J, Lalonde E, Ewens KG, Ebrahimzadeh J, Richard-Yutz J, Shields CL, Barrera A, Green CJ, Barash Y, Ganguly A. PRiMeUM: A Model for Predicting Risk of Metastasis in Uveal Melanoma. Invest Ophthalmol Vis Sci. 2017;58:4096\u2013105. https:\/\/doi.org\/10.1167\/iovs.17-22255.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1684_CR39","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/s41571-022-00714-1","volume":"20","author":"RD Carvajal","year":"2023","unstructured":"Carvajal RD, Sacco JJ, Jager MJ, Eschelman DJ, Olofsson Bagge R, Harbour JW, Chieng ND, Patel SP, Joshua AM, Piperno-Neumann S. Advances in the clinical management of uveal melanoma. Nat Rev Clin Oncol. 2023;20:99\u2013115. https:\/\/doi.org\/10.1038\/s41571-022-00714-1.","journal-title":"Nat Rev Clin Oncol"},{"key":"1684_CR40","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1158\/1078-0432.ccr-15-2071","volume":"22","author":"MG Field","year":"2016","unstructured":"Field MG, Decatur CL, Kurtenbach S, Gezgin G, van der Velden PA, Jager MJ, Kozak KN, Harbour JW. PRAME as an Independent Biomarker for Metastasis in Uveal Melanoma. Clin Cancer Res. 2016;22:1234\u201342. https:\/\/doi.org\/10.1158\/1078-0432.ccr-15-2071.","journal-title":"Clin Cancer Res"},{"key":"1684_CR41","doi-asserted-by":"publisher","unstructured":"Harbour JW. Correa ZM. Schefler AC. Mruthyunjaya P. Materin MA. Aaberg TA. Skalet AH. Reichstein DA. Weis E. Kim IK et al. 15-Gene Expression Profile and PRAME as Integrated Prognostic Test for Uveal Melanoma: First Report of Collaborative Ocular Oncology Group Study No. 2 (COOG2.1). J Clin Oncol 2024;42:3319\u20133329\u00a0https:\/\/doi.org\/10.1200\/JCO.24.00447.","DOI":"10.1200\/JCO.24.00447"},{"key":"1684_CR42","doi-asserted-by":"publisher","first-page":"59209","DOI":"10.18632\/oncotarget.10962","volume":"7","author":"MG Field","year":"2016","unstructured":"Field MG, Durante MA, Decatur CL, Tarlan B, Oelschlager KM, Stone JF, Kuznetsov J, Bowcock AM, Kurtenbach S, Harbour JW. Epigenetic reprogramming and aberrant expression of PRAME are associated with increased metastatic risk in Class 1 and Class 2 uveal melanomas. Oncotarget. 2016;7:59209\u201319. https:\/\/doi.org\/10.18632\/oncotarget.10962.","journal-title":"Oncotarget"},{"key":"1684_CR43","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1016\/j.ejso.2009.02.016","volume":"35","author":"P Mariani","year":"2009","unstructured":"Mariani P, Piperno-Neumann S, Servois V, Berry MG, Dorval T, Plancher C, Couturier J, Levy-Gabriel C, Lumbroso-Le Rouic L, Desjardins L, et al. Surgical management of liver metastases from uveal melanoma: 16 years\u2019 experience at the Institut Curie. Eur J Surg Oncol. 2009;35:1192\u20137. https:\/\/doi.org\/10.1016\/j.ejso.2009.02.016.","journal-title":"Eur J Surg Oncol"},{"key":"1684_CR44","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1097\/CMR.0000000000000867","volume":"33","author":"DB Trivedi","year":"2023","unstructured":"Trivedi DB, Aldulaimi N, Karydis I, Wheater M, Modi S, Stedman B, Karavias D, Primrose J, Pearce N, Takhar AS. Liver resection for metastatic uveal melanoma: experience from a supra-regional centre and review of literature. Melanoma Res. 2023;33:71\u20139. https:\/\/doi.org\/10.1097\/CMR.0000000000000867.","journal-title":"Melanoma Res"},{"key":"1684_CR45","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1245\/ASO.2005.06.032","volume":"12","author":"M Rivoire","year":"2005","unstructured":"Rivoire M, Kodjikian L, Baldo S, Kaemmerlen P, Negrier S, Grange JD. Treatment of liver metastases from uveal melanoma. Ann Surg Oncol. 2005;12:422\u20138. https:\/\/doi.org\/10.1245\/ASO.2005.06.032.","journal-title":"Ann Surg Oncol"},{"key":"1684_CR46","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/s0748-7983(98)91485-8","volume":"24","author":"RJ Salmon","year":"1998","unstructured":"Salmon RJ, Levy C, Plancher C, Dorval T, Desjardins L, Leyvraz S, Pouillart P, Schlienger P, Servois V, Asselain B. Treatment of liver metastases from uveal melanoma by combined surgery-chemotherapy. Eur J Surg Oncol. 1998;24:127\u201330. https:\/\/doi.org\/10.1016\/s0748-7983(98)91485-8.","journal-title":"Eur J Surg Oncol"},{"key":"1684_CR47","doi-asserted-by":"publisher","first-page":"13","DOI":"10.15761\/TiT.1000282","volume":"2020","author":"S Dueland","year":"2020","unstructured":"Dueland S, Solheim J, Foss A, Grut H, Hagness M, Line P-D. Dismal survival following liver transplantation for liver-only metastases in patients with ocular malignant melanoma. Trends in Transplantation. 2020;2020:13. https:\/\/doi.org\/10.15761\/TiT.1000282.","journal-title":"Trends in Transplantation"},{"key":"1684_CR48","doi-asserted-by":"publisher","unstructured":"de Brito RV. Mancini MW. Palumbo MDN. Moraes LHO. Rodrigues GJ. Cervantes O. Sercarz JA. Paiva MB. The Rationale for \"Laser-Induced Thermal Therapy (LITT) and Intratumoral Cisplatin\" Approach for Cancer Treatment. Int J Mol Sci 2022;23\u00a0https:\/\/doi.org\/10.3390\/ijms23115934.","DOI":"10.3390\/ijms23115934"},{"key":"1684_CR49","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1007\/s00270-016-1336-z","volume":"39","author":"R Bale","year":"2016","unstructured":"Bale R, Schullian P, Schmuth M, Widmann G, Jaschke W, Weinlich G. Stereotactic Radiofrequency Ablation for Metastatic Melanoma to the Liver. Cardiovasc Intervent Radiol. 2016;39:1128\u201335. https:\/\/doi.org\/10.1007\/s00270-016-1336-z.","journal-title":"Cardiovasc Intervent Radiol"},{"key":"1684_CR50","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1016\/j.ejso.2016.02.019","volume":"42","author":"P Mariani","year":"2016","unstructured":"Mariani P, Almubarak MM, Kollen M, Wagner M, Plancher C, Audollent R, Piperno-Neumann S, Cassoux N, Servois V. Radiofrequency ablation and surgical resection of liver metastases from uveal melanoma. Eur J Surg Oncol. 2016;42:706\u201312. https:\/\/doi.org\/10.1016\/j.ejso.2016.02.019.","journal-title":"Eur J Surg Oncol"},{"key":"1684_CR51","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1111\/jdv.12405","volume":"28","author":"K Eichler","year":"2014","unstructured":"Eichler K, Zangos S, Gruber-Rouh T, Vogl TJ, Mack MG. MR-guided laser-induced thermotherapy (LITT) in patients with liver metastases of uveal melanoma. J Eur Acad Dermatol Venereol. 2014;28:1756\u201360. https:\/\/doi.org\/10.1111\/jdv.12405.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1684_CR52","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.soc.2020.08.005","volume":"30","author":"LC Connell","year":"2021","unstructured":"Connell LC, Kemeny NE. Intraarterial Chemotherapy for Liver Metastases. Surg Oncol Clin N Am. 2021;30:143\u201358. https:\/\/doi.org\/10.1016\/j.soc.2020.08.005.","journal-title":"Surg Oncol Clin N Am"},{"key":"1684_CR53","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1053\/j.seminoncol.2010.03.014","volume":"37","author":"T Sato","year":"2010","unstructured":"Sato T. Locoregional management of hepatic metastasis from primary uveal melanoma. Semin Oncol. 2010;37:127\u201338. https:\/\/doi.org\/10.1053\/j.seminoncol.2010.03.014.","journal-title":"Semin Oncol"},{"key":"1684_CR54","first-page":"1157","volume":"56","author":"B Melichar","year":"2009","unstructured":"Melichar B, Voboril Z, Lojik M, Krajina A. Liver metastases from uveal melanoma: clinical experience of hepatic arterial infusion of cisplatin, vinblastine and dacarbazine. Hepatogastroenterology. 2009;56:1157\u201362.","journal-title":"Hepatogastroenterology"},{"key":"1684_CR55","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1093\/annonc\/mdt585","volume":"25","author":"S Leyvraz","year":"2014","unstructured":"Leyvraz S, Piperno-Neumann S, Suciu S, Baurain JF, Zdzienicki M, Testori A, Marshall E, Scheulen M, Jouary T, Negrier S, et al. Hepatic intra-arterial versus intravenous fotemustine in patients with liver metastases from uveal melanoma (EORTC 18021): a multicentric randomized trial. Ann Oncol. 2014;25:742\u20136. https:\/\/doi.org\/10.1093\/annonc\/mdt585.","journal-title":"Ann Oncol"},{"key":"1684_CR56","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000006255","author":"R Olofsson Bagge","year":"2024","unstructured":"Olofsson Bagge R, Nelson A, Shafazand A, All-Eriksson C, Cahlin C, Elander N, Gustavsson A, Helgadottir H, Kiilgaard JF, Kinhult S, et al. Survival and Quality of Life after Isolated Hepatic Perfusion with Melphalan as a Treatment for Uveal Melanoma Liver Metastases - Final Results from the Phase III Randomized Controlled Trial SCANDIUM. Ann Surg. 2024. https:\/\/doi.org\/10.1097\/SLA.0000000000006255.","journal-title":"Ann Surg"},{"key":"1684_CR57","doi-asserted-by":"publisher","first-page":"5340","DOI":"10.1245\/s10434-024-15293-x","volume":"31","author":"JS Zager","year":"2024","unstructured":"Zager JS, Orloff M, Ferrucci PF, Choi J, Eschelman DJ, Glazer ES, Ejaz A, Howard JH, Richtig E, Ochsenreither S, et al. Efficacy and Safety of the Melphalan\/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter Phase 3 Study. Ann Surg Oncol. 2024;31:5340\u201351. https:\/\/doi.org\/10.1245\/s10434-024-15293-x.","journal-title":"Ann Surg Oncol"},{"key":"1684_CR58","doi-asserted-by":"crossref","unstructured":"Carrasco CH. Wallace S. Charnsangavej C. Papadopoulos NE. Patt YZ. Mavligit GM. Treatment of hepatic metastases in ocular melanoma. Embolization of the hepatic artery with polyvinyl sponge and cisplatin. JAMA 1986;255:3152\u20133154.","DOI":"10.1001\/jama.1986.03370220114038"},{"key":"1684_CR59","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1055\/s-0043-1777716","volume":"41","author":"DM DePietro","year":"2024","unstructured":"DePietro DM, Li X, Shamimi-Noori SM. Chemoembolization Beyond Hepatocellular Carcinoma: What Tumors Can We Treat and When? Semin Intervent Radiol. 2024;41:27\u201347. https:\/\/doi.org\/10.1055\/s-0043-1777716.","journal-title":"Semin Intervent Radiol"},{"key":"1684_CR60","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1001\/archophthalmol.2009.45","volume":"127","author":"PN Dayani","year":"2009","unstructured":"Dayani PN, Gould JE, Brown DB, Sharma KV, Linette GP, Harbour JW. Hepatic metastasis from uveal melanoma: angiographic pattern predictive of survival after hepatic arterial chemoembolization. Arch Ophthalmol. 2009;127:628\u201332. https:\/\/doi.org\/10.1001\/archophthalmol.2009.45.","journal-title":"Arch Ophthalmol"},{"key":"1684_CR61","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1097\/CMR.0000000000000129","volume":"25","author":"S Valpione","year":"2015","unstructured":"Valpione S, Aliberti C, Parrozzani R, Bazzi M, Pigozzo J, Midena E, Pilati P, Campana LG, Chiarion-Sileni V. A retrospective analysis of 141 patients with liver metastases from uveal melanoma: a two-cohort study comparing transarterial chemoembolization with CPT-11 charged microbeads and historical treatments. Melanoma Res. 2015;25:164\u20138. https:\/\/doi.org\/10.1097\/CMR.0000000000000129.","journal-title":"Melanoma Res"},{"key":"1684_CR62","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1148\/radiol.2521081252","volume":"252","author":"A Yamamoto","year":"2009","unstructured":"Yamamoto A, Chervoneva I, Sullivan KL, Eschelman DJ, Gonsalves CF, Mastrangelo MJ, Berd D, Shields JA, Shields CL, Terai M, et al. High-dose immunoembolization: survival benefit in patients with hepatic metastases from uveal melanoma. Radiology. 2009;252:290\u20138. https:\/\/doi.org\/10.1148\/radiol.2521081252.","journal-title":"Radiology"},{"key":"1684_CR63","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.jvir.2014.11.037","volume":"26","author":"ME Valsecchi","year":"2015","unstructured":"Valsecchi ME, Terai M, Eschelman DJ, Gonsalves CF, Chervoneva I, Shields JA, Shields CL, Yamamoto A, Sullivan KL, Laudadio M, et al. Double-blinded, randomized phase II study using embolization with or without granulocyte-macrophage colony-stimulating factor in uveal melanoma with hepatic metastases. J Vasc Interv Radiol. 2015;26:523-532.e522. https:\/\/doi.org\/10.1016\/j.jvir.2014.11.037.","journal-title":"J Vasc Interv Radiol"},{"key":"1684_CR64","doi-asserted-by":"publisher","first-page":"9511","DOI":"10.1200\/JCO.2022.40.16_suppl.9511","volume":"40","author":"C-AA Peuker","year":"2022","unstructured":"Peuker C-AA, Bucourt MD, Gebauer B, Amthauer H, Erxleben C, Eucker J, Keller U, Leyvraz S, Joussen AM, Keilholz U, et al. First interim analysis of the SirTac trial: A randomized phase II study of SIRT and DSM-TACE in patients with liver metastases from uveal melanoma. J Clin Oncol. 2022;40:9511\u20139511. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.9511.","journal-title":"J Clin Oncol"},{"key":"1684_CR65","doi-asserted-by":"publisher","first-page":"9031","DOI":"10.1200\/jco.2013.31.15_suppl.9031","volume":"31","author":"JJ Sacco","year":"2013","unstructured":"Sacco JJ, Nathan PD, Danson S, Lorigan P, Nicholson S, Ottensmeier C, Corrie P, Steven N, Goodman A, Larkin JMG, et al. Sunitinib versus dacarbazine as first-line treatment in patients with metastatic uveal melanoma. J Clin Oncol. 2013;31:9031\u20139031. https:\/\/doi.org\/10.1200\/jco.2013.31.15_suppl.9031.","journal-title":"J Clin Oncol"},{"key":"1684_CR66","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1158\/1078-0432.CCR-19-1223","volume":"26","author":"JJ Luke","year":"2020","unstructured":"Luke JJ, Olson DJ, Allred JB, Strand CA, Bao R, Zha Y, Carll T, Labadie BW, Bastos BR, Butler MO, et al. Randomized Phase II Trial and Tumor Mutational Spectrum Analysis from Cabozantinib versus Chemotherapy in Metastatic Uveal Melanoma (Alliance A091201). Clin Cancer Res. 2020;26:804\u201311. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-1223.","journal-title":"Clin Cancer Res"},{"key":"1684_CR67","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.3892\/etm.2021.10863","volume":"22","author":"DC Branisteanu","year":"2021","unstructured":"Branisteanu DC, Bogdanici CM, Branisteanu DE, Maranduca MA, Zemba M, Balta F, Branisteanu CI, Moraru AD. Uveal melanoma diagnosis and current treatment options (Review). Exp Ther Med. 2021;22:1428. https:\/\/doi.org\/10.3892\/etm.2021.10863.","journal-title":"Exp Ther Med"},{"key":"1684_CR68","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s40487-018-0056-8","volume":"6","author":"M Singh","year":"2018","unstructured":"Singh M, Durairaj P, Yeung J. Uveal Melanoma: A Review of the Literature. Oncol Ther. 2018;6:87\u2013104. https:\/\/doi.org\/10.1007\/s40487-018-0056-8.","journal-title":"Oncol Ther"},{"key":"1684_CR69","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1097\/CMR.0000000000000401","volume":"27","author":"G Schinzari","year":"2017","unstructured":"Schinzari G, Rossi E, Cassano A, Dadduzio V, Quirino M, Pagliara M, Blasi MA, Barone C. Cisplatin, dacarbazine and vinblastine as first line chemotherapy for liver metastatic uveal melanoma in the era of immunotherapy: a single institution phase II study. Melanoma Res. 2017;27:591\u20135. https:\/\/doi.org\/10.1097\/CMR.0000000000000401.","journal-title":"Melanoma Res"},{"key":"1684_CR70","doi-asserted-by":"publisher","unstructured":"Theocharopoulos C. Lialios PP. Samarkos M. Gogas H. Ziogas DC. Antibody-Drug Conjugates: Functional Principles and Applications in Oncology and Beyond. Vaccines (Basel) 2021;9: https:\/\/doi.org\/10.3390\/vaccines9101111.","DOI":"10.3390\/vaccines9101111"},{"key":"1684_CR71","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2024.102806","volume":"129","author":"C Theocharopoulos","year":"2024","unstructured":"Theocharopoulos C, Ziogas IA, Douligeris C-C, Efstathiou A, Kolorizos E, Ziogas DC, Kontis E. Antibody-drug conjugates for hepato-pancreato-biliary malignancies: \u201cMagic bullets\u201d to the rescue? Cancer Treat Rev. 2024;129. https:\/\/doi.org\/10.1016\/j.ctrv.2024.102806.","journal-title":"Cancer Treat Rev"},{"key":"1684_CR72","doi-asserted-by":"publisher","first-page":"175883592096299","DOI":"10.1177\/1758835920962997","volume":"12","author":"C Theocharopoulos","year":"2020","unstructured":"Theocharopoulos C, Lialios PP, Gogas H, Ziogas DC. An overview of antibody-drug conjugates in oncological practice. Ther Adv Med Oncol. 2020;12:1758835920962997. https:\/\/doi.org\/10.1177\/1758835920962997.","journal-title":"Ther Adv Med Oncol"},{"key":"1684_CR73","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1007\/s10637-019-00832-1","volume":"38","author":"S Sandhu","year":"2020","unstructured":"Sandhu S, McNeil CM, LoRusso P, Patel MR, Kabbarah O, Li C, Sanabria S, Flanagan WM, Yeh RF, Brunstein F, et al. Phase I study of the anti-endothelin B receptor antibody-drug conjugate DEDN6526A in patients with metastatic or unresectable cutaneous, mucosal, or uveal melanoma. Invest New Drugs. 2020;38:844\u201354. https:\/\/doi.org\/10.1007\/s10637-019-00832-1.","journal-title":"Invest New Drugs"},{"key":"1684_CR74","doi-asserted-by":"publisher","unstructured":"Hasanov M. Rioth MJ. Kendra K. Hernandez-Aya L. Joseph RW. Williamson S. Chandra S. Shirai K. Turner CD. Lewis K et al. A Phase II Study of Glembatumumab Vedotin for Metastatic Uveal Melanoma. Cancers (Basel) 2020;12: https:\/\/doi.org\/10.3390\/cancers12082270.","DOI":"10.3390\/cancers12082270"},{"key":"1684_CR75","doi-asserted-by":"publisher","unstructured":"Wk J. D'Alessio JA. Yerramilli-Rao P. Blankenship J. Buntin K. Burger M. Chen Z. Cho YS. Davis J. Ebel N et al. Abstract IA022: DYP688, a first-in-class PMEL17-targeted antibody drug conjugate delivering a Gq\/11-specific inhibitor for the treatment of metastatic uveal melanoma. Mol Cancer Ther\u00a02024;23:IA022-IA022, https:\/\/doi.org\/10.1158\/1538-8514.Cancerchem24-ia022.","DOI":"10.1158\/1538-8514.Cancerchem24-ia022"},{"key":"1684_CR76","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2022.102499","volume":"113","author":"DC Ziogas","year":"2022","unstructured":"Ziogas DC, Theocharopoulos C, Koutouratsas T, Haanen J, Gogas H. Mechanisms of resistance to immune checkpoint inhibitors in melanoma: What we have to overcome? Cancer Treat Rev. 2022;113. https:\/\/doi.org\/10.1016\/j.ctrv.2022.102499.","journal-title":"Cancer Treat Rev"},{"key":"1684_CR77","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s00262-011-1089-0","volume":"61","author":"R Danielli","year":"2012","unstructured":"Danielli R, Ridolfi R, Chiarion-Sileni V, Queirolo P, Testori A, Plummer R, Boitano M, Calabr\u00f2 L, Rossi CD, Giacomo AM, et al. Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy. Cancer Immunol Immunother. 2012;61:41\u20138. https:\/\/doi.org\/10.1007\/s00262-011-1089-0.","journal-title":"Cancer Immunol Immunother"},{"key":"1684_CR78","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0118564","volume":"10","author":"L Zimmer","year":"2015","unstructured":"Zimmer L, Vaubel J, Mohr P, Hauschild A, Utikal J, Simon J, Garbe C, Herbst R, Enk A, K\u00e4mpgen E, et al. Phase II DeCOG-study of ipilimumab in pretreated and treatment-na\u00efve patients with metastatic uveal melanoma. PLoS ONE. 2015;10. https:\/\/doi.org\/10.1371\/journal.pone.0118564.","journal-title":"PLoS ONE"},{"key":"1684_CR79","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1097\/cmr.0000000000000653","volume":"30","author":"EA Rozeman","year":"2020","unstructured":"Rozeman EA, Prevoo W, Meier MAJ, Sikorska K, Van TM, van de Wiel BA, van der Wal JE, Mallo HA, Grijpink-Ongering LG, Broeks A, et al. Phase Ib\/II trial testing combined radiofrequency ablation and ipilimumab in uveal melanoma (SECIRA-UM). Melanoma Res. 2020;30:252\u201360. https:\/\/doi.org\/10.1097\/cmr.0000000000000653.","journal-title":"Melanoma Res"},{"key":"1684_CR80","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2016.1143997","volume":"5","author":"I Karydis","year":"2016","unstructured":"Karydis I, Chan PY, Wheater M, Arriola E, Szlosarek PW, Ottensmeier CH. Clinical activity and safety of Pembrolizumab in Ipilimumab pre-treated patients with uveal melanoma. Oncoimmunology. 2016;5. https:\/\/doi.org\/10.1080\/2162402x.2016.1143997.","journal-title":"Oncoimmunology"},{"key":"1684_CR81","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1007\/s00262-019-02352-6","volume":"68","author":"E Rossi","year":"2019","unstructured":"Rossi E, Pagliara MM, Orteschi D, Dosa T, Sammarco MG, Caputo CG, Petrone G, Rindi G, Zollino M, Blasi MA, et al. Pembrolizumab as first-line treatment for metastatic uveal melanoma. Cancer Immunol Immunother. 2019;68:1179\u201385. https:\/\/doi.org\/10.1007\/s00262-019-02352-6.","journal-title":"Cancer Immunol Immunother"},{"key":"1684_CR82","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1097\/CMR.0000000000000175","volume":"25","author":"AM Joshua","year":"2015","unstructured":"Joshua AM, Monzon JG, Mihalcioiu C, Hogg D, Smylie M, Cheng T. A phase 2 study of tremelimumab in patients with advanced uveal melanoma. Melanoma Res. 2015;25:342\u20137. https:\/\/doi.org\/10.1097\/CMR.0000000000000175.","journal-title":"Melanoma Res"},{"key":"1684_CR83","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1200\/jco.20.00550","volume":"39","author":"JM Piulats","year":"2021","unstructured":"Piulats JM, Espinosa E, de la Cruz Merino L, Varela M, Alonso Carri\u00f3n L, Mart\u00edn-Algarra S, L\u00f3pez Castro R, Curiel T, Rodr\u00edguez-Abreu D, Redrado M, et al. Nivolumab Plus Ipilimumab for Treatment-Na\u00efve Metastatic Uveal Melanoma: An Open-Label, Multicenter, Phase II Trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402). J Clin Oncol. 2021;39:586\u201398. https:\/\/doi.org\/10.1200\/jco.20.00550.","journal-title":"J Clin Oncol"},{"key":"1684_CR84","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1200\/JCO.20.00605","volume":"39","author":"MS Pelster","year":"2021","unstructured":"Pelster MS, Gruschkus SK, Bassett R, Gombos DS, Shephard M, Posada L, Glover MS, Simien R, Diab A, Hwu P, et al. Nivolumab and Ipilimumab in Metastatic Uveal Melanoma: Results From a Single-Arm Phase II Study. J Clin Oncol. 2021;39:599\u2013607. https:\/\/doi.org\/10.1200\/JCO.20.00605.","journal-title":"J Clin Oncol"},{"key":"1684_CR85","doi-asserted-by":"publisher","unstructured":"Najjar, Y.G.; Navrazhina, K.; Ding, F.; Bhatia, R.; Tsai, K.; Abbate, K.; Durden, B.; Eroglu, Z.; Bhatia, S.; Park, S.; et al. Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study. J Immunother Cancer 2020, 8, https:\/\/doi.org\/10.1136\/jitc-2019-000331.","DOI":"10.1136\/jitc-2019-000331"},{"key":"1684_CR86","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1186\/s40425-019-0800-0","volume":"7","author":"MV Heppt","year":"2019","unstructured":"Heppt MV, Amaral T, Kahler KC, Heinzerling L, Hassel JC, Meissner M, Kreuzberg N, Loquai C, Reinhardt L, Utikal J, et al. Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study. J Immunother Cancer. 2019;7:299. https:\/\/doi.org\/10.1186\/s40425-019-0800-0.","journal-title":"J Immunother Cancer"},{"key":"1684_CR87","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1007\/s00270-022-03338-1","volume":"46","author":"TML Tong","year":"2023","unstructured":"Tong TML, Burgmans MC, Speetjens FM, van Erkel AR, van der Meer RW, van Rijswijk CSP, Jonker-Bos MA, Roozen CFM, Sporrel-Blokland M, Lutjeboer J, et al. Combining Melphalan Percutaneous Hepatic Perfusion with Ipilimumab Plus Nivolumab in Advanced Uveal Melanoma: First Safety and Efficacy Data from the Phase Ib Part of the Chopin Trial. Cardiovasc Intervent Radiol. 2023;46:350\u20139. https:\/\/doi.org\/10.1007\/s00270-022-03338-1.","journal-title":"Cardiovasc Intervent Radiol"},{"key":"1684_CR88","doi-asserted-by":"publisher","first-page":"5881","DOI":"10.1158\/1538-7445.Am2023-5881","volume":"83","author":"SP Patel","year":"2023","unstructured":"Patel SP, Haymaker C, Sheth RA, Kuban JD, Weintraub J, Wehrenberg-Klee E, Novelli P, Gonsalves C, Adamo R, Honaker V, et al. Abstract 5881: PERIO-01: Initial safety experience and immunologic effects of a Class C TLR9 agonist using pressure- enabled drug delivery in a phase 1 trial of hepatic arterial infusion of SD-101 +\/- checkpoint inhibition in metastatic uveal melanoma. Can Res. 2023;83:5881\u20135881. https:\/\/doi.org\/10.1158\/1538-7445.Am2023-5881.","journal-title":"Can Res"},{"key":"1684_CR89","doi-asserted-by":"publisher","first-page":"S741","DOI":"10.1016\/j.annonc.2024.08.1194","volume":"35","author":"J Lutzky","year":"2024","unstructured":"Lutzky J, Hernandez-Aya L, Feun L, Correa Z, King J, Estevez C, Decatur C, Dollar JJ, Reis I, Harbour JW. 1126P A phase II study of nivolumab\/relatlimab in metastatic uveal melanoma. Ann Oncol. 2024;35:S741. https:\/\/doi.org\/10.1016\/j.annonc.2024.08.1194.","journal-title":"Ann Oncol"},{"key":"1684_CR90","doi-asserted-by":"publisher","unstructured":"Natale, C.A.; Li, J.; Zhang, J.; Dahal, A.; Dentchev, T.; Stanger, B.Z.; Ridky, T.W. Activation of G protein-coupled estrogen receptor signaling inhibits melanoma and improves response to immune checkpoint blockade. Elife 2018, 7, https:\/\/doi.org\/10.7554\/eLife.31770.","DOI":"10.7554\/eLife.31770"},{"key":"1684_CR91","doi-asserted-by":"publisher","first-page":"9543","DOI":"10.1200\/JCO.2023.41.16_suppl.9543","volume":"41","author":"A Shoushtari","year":"2023","unstructured":"Shoushtari A, Chaney M, Cohen J, Garyantes T, Lin J, Ishizuka J, Mita A, Mita M, Muller C, Natale C, et al. The effect of LNS8801 alone and in combination with pembrolizumab in patients with metastatic uveal melanoma. J Clin Oncol. 2023;41:9543\u20139543. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.9543.","journal-title":"J Clin Oncol"},{"key":"1684_CR92","doi-asserted-by":"crossref","unstructured":"Wu, L.; Maki, C.G. MDM2: RING Finger Protein and Regulator of p53. In Zinc Finger Proteins: From Atomic Contact to Cellular Function, Iuchi, S., Kuldell, N., Eds.; Springer US: Boston, MA, 2005; pp. 252\u2013260.","DOI":"10.1007\/0-387-27421-9_34"},{"key":"1684_CR93","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1186\/s40425-019-0750-6","volume":"7","author":"DD Fang","year":"2019","unstructured":"Fang DD, Tang Q, Kong Y, Wang Q, Gu J, Fang X, Zou P, Rong T, Wang J, Yang D, et al. MDM2 inhibitor APG-115 synergizes with PD-1 blockade through enhancing antitumor immunity in the tumor microenvironment. J Immunother Cancer. 2019;7:327. https:\/\/doi.org\/10.1186\/s40425-019-0750-6.","journal-title":"J Immunother Cancer"},{"key":"1684_CR94","doi-asserted-by":"publisher","first-page":"9517","DOI":"10.1200\/JCO.2022.40.16_suppl.9517","volume":"40","author":"M McKean","year":"2022","unstructured":"McKean M, Tolcher AW, Reeves JA, Chmielowski B, Shaheen MF, Beck JT, Orloff MM, Somaiah N, Tine BAV, Drabick JJ, et al. Newly updated activity results of alrizomadlin (APG-115), a novel MDM2\/p53 inhibitor, plus pembrolizumab: Phase 2 study in adults and children with various solid tumors. J Clin Oncol. 2022;40:9517\u20139517. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.9517.","journal-title":"J Clin Oncol"},{"key":"1684_CR95","doi-asserted-by":"publisher","unstructured":"Ziogas, D.C.; Theocharopoulos, C.; Lialios, P.P.; Foteinou, D.; Koumprentziotis, I.A.; Xynos, G.; Gogas, H. Beyond CTLA-4 and PD-1 Inhibition: Novel Immune Checkpoint Molecules for Melanoma Treatment. Cancers (Basel) 2023, 15, https:\/\/doi.org\/10.3390\/cancers15102718.","DOI":"10.3390\/cancers15102718"},{"key":"1684_CR96","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.ajo.2014.07.014","volume":"158","author":"KF Bol","year":"2014","unstructured":"Bol KF, Mensink HW, Aarntzen EH, Schreibelt G, Keunen JE, Coulie PG, de Klein A, Punt CJ, Paridaens D, Figdor CG, et al. Long overall survival after dendritic cell vaccination in metastatic uveal melanoma patients. Am J Ophthalmol. 2014;158:939\u201347. https:\/\/doi.org\/10.1016\/j.ajo.2014.07.014.","journal-title":"Am J Ophthalmol"},{"key":"1684_CR97","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.785231","volume":"13","author":"EAT Koch","year":"2022","unstructured":"Koch EAT, Schaft N, Kummer M, Berking C, Schuler G, Hasumi K, Dorrie J, Schuler-Thurner B. A One-Armed Phase I Dose Escalation Trial Design: Personalized Vaccination with IKKbeta-Matured, RNA-Loaded Dendritic Cells for Metastatic Uveal Melanoma. Front Immunol. 2022;13. https:\/\/doi.org\/10.3389\/fimmu.2022.785231.","journal-title":"Front Immunol"},{"key":"1684_CR98","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/s41392-023-01407-6","volume":"8","author":"D Lin","year":"2023","unstructured":"Lin D, Shen Y, Liang T. Oncolytic virotherapy: basic principles, recent advances and future directions. Signal Transduct Target Ther. 2023;8:156. https:\/\/doi.org\/10.1038\/s41392-023-01407-6.","journal-title":"Signal Transduct Target Ther"},{"key":"1684_CR99","doi-asserted-by":"publisher","first-page":"9511","DOI":"10.1200\/JCO.2024.42.16_suppl.9511","volume":"42","author":"JJ Sacco","year":"2024","unstructured":"Sacco JJ, Harrington KJ, Olsson-Brown A, Chan TY, Nenclares P, Leslie I, Bommareddy P, Kalbasi A, Xie B, Mishal M, et al. Safety, efficacy, and biomarker results from an open-label, multicenter, phase 1 study of RP2 alone or combined with nivolumab in a cohort of patients with uveal melanoma. J Clin Oncol. 2024;42:9511\u20139511. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.9511.","journal-title":"J Clin Oncol"},{"key":"1684_CR100","doi-asserted-by":"publisher","first-page":"1279387","DOI":"10.3389\/fimmu.2023.1279387","volume":"14","author":"KER Smith","year":"2023","unstructured":"Smith KER, Peng KW, Pulido JS, Weisbrod AJ, Strand CA, Allred JB, Newsom AN, Zhang L, Packiriswamy N, Kottke T, et al. A phase I oncolytic virus trial with vesicular stomatitis virus expressing human interferon beta and tyrosinase related protein 1 administered intratumorally and intravenously in uveal melanoma: safety, efficacy, and T cell responses. Front Immunol. 2023;14:1279387. https:\/\/doi.org\/10.3389\/fimmu.2023.1279387.","journal-title":"Front Immunol"},{"key":"1684_CR101","doi-asserted-by":"publisher","first-page":"6059","DOI":"10.1007\/s00432-022-04510-3","volume":"149","author":"J Lutzky","year":"2023","unstructured":"Lutzky J, Sullivan RJ, Cohen JV, Ren Y, Li A, Haq R. Phase 1b study of intravenous coxsackievirus A21 (V937) and ipilimumab for patients with metastatic uveal melanoma. J Cancer Res Clin Oncol. 2023;149:6059\u201366. https:\/\/doi.org\/10.1007\/s00432-022-04510-3.","journal-title":"J Cancer Res Clin Oncol"},{"key":"1684_CR102","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1089\/hum.2018.107","volume":"30","author":"M Garcia","year":"2019","unstructured":"Garcia M, Moreno R, Gil-Martin M, Cascallo M, de Olza MO, Cuadra C, Piulats JM, Navarro V, Domenech M, Alemany R, et al. A Phase 1 Trial of Oncolytic Adenovirus ICOVIR-5 Administered Intravenously to Cutaneous and Uveal Melanoma Patients. Hum Gene Ther. 2019;30:352\u201364. https:\/\/doi.org\/10.1089\/hum.2018.107.","journal-title":"Hum Gene Ther"},{"key":"1684_CR103","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/S1470-2045(17)30251-6","volume":"18","author":"SS Chandran","year":"2017","unstructured":"Chandran SS, Somerville RPT, Yang JC, Sherry RM, Klebanoff CA, Goff SL, Wunderlich JR, Danforth DN, Zlott D, Paria BC, et al. Treatment of metastatic uveal melanoma with adoptive transfer of tumour-infiltrating lymphocytes: a single-centre, two-stage, single-arm, phase 2 study. Lancet Oncol. 2017;18:792\u2013802. https:\/\/doi.org\/10.1016\/S1470-2045(17)30251-6.","journal-title":"Lancet Oncol"},{"key":"1684_CR104","doi-asserted-by":"publisher","first-page":"9513","DOI":"10.1200\/JCO.2023.41.16_suppl.9513","volume":"41","author":"SP Patel","year":"2023","unstructured":"Patel SP, Forget M-A, Kreidieh FY, Pelster M, Davies MA, Amaria RN, Gombos DS, Bernatchez C. Tumor infiltrating lymphocyte (TIL) harvest and ex vivo expansion from primary and metastatic (met) uveal melanoma (UM) tumors. J Clin Oncol. 2023;41:9513\u20139513. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.9513.","journal-title":"J Clin Oncol"},{"key":"1684_CR105","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1056\/NEJMoa2304753","volume":"389","author":"JC Hassel","year":"2023","unstructured":"Hassel JC, Piperno-Neumann S, Rutkowski P, Baurain JF, Schlaak M, Butler MO, Sullivan RJ, Dummer R, Kirkwood JM, Orloff M, et al. Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma. N Engl J Med. 2023;389:2256\u201366. https:\/\/doi.org\/10.1056\/NEJMoa2304753.","journal-title":"N Engl J Med"},{"key":"1684_CR106","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.115161","volume":"214","author":"F Dimitriou","year":"2025","unstructured":"Dimitriou F, Orloff MM, Koch Hein EC, Cheng PF, Hughes IF, Simeone E, Montazeri K, Grover P, Mehmi I, Gerard CL, et al. Treatment sequence with tebentafusp and immune checkpoint inhibitors in patients with metastatic uveal melanoma and metastatic GNA11\/GNAQ mutant melanocytic tumors. Eur J Cancer. 2025;214. https:\/\/doi.org\/10.1016\/j.ejca.2024.115161.","journal-title":"Eur J Cancer"},{"key":"1684_CR107","doi-asserted-by":"publisher","unstructured":"Tomsitz, D.; Ruf, T.; Heppt, M.; Staeger, R.; Ramelyte, E.; Dummer, R.; Garzarolli, M.; Meier, F.; Meier, E.; Richly, H.; et al. Tebentafusp in Patients with Metastatic Uveal Melanoma: A Real-Life Retrospective Multicenter Study. Cancers (Basel) 2023, 15, https:\/\/doi.org\/10.3390\/cancers15133430.","DOI":"10.3390\/cancers15133430"},{"key":"1684_CR108","doi-asserted-by":"publisher","unstructured":"Koch, E.C.; Arteaga Ceballos, D.P.; Vilbert, M.; Lajkosz, K.; Pimentel Muniz, T.; Hirsch, I.; Silva Almeida Ribeiro, M.F.; Mantle, L.; Anczurowski, M.; Hogg, D.; et al. 831P Outcomes of immune checkpoint inhibitors in patients with metastatic uveal melanoma treated with tebentafusp. Annals of Oncology 2022, 33, S928, https:\/\/doi.org\/10.1016\/j.annonc.2022.07.957.","DOI":"10.1016\/j.annonc.2022.07.957"},{"key":"1684_CR109","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1038\/sj.bjc.6602598","volume":"92","author":"W Zuidervaart","year":"2005","unstructured":"Zuidervaart W, van Nieuwpoort F, Stark M, Dijkman R, Packer L, Borgstein AM, Pavey S, van der Velden P, Out C, Jager MJ, et al. Activation of the MAPK pathway is a common event in uveal melanomas although it rarely occurs through mutation of BRAF or RAS. Br J Cancer. 2005;92:2032\u20138. https:\/\/doi.org\/10.1038\/sj.bjc.6602598.","journal-title":"Br J Cancer"},{"key":"1684_CR110","first-page":"5712","volume":"63","author":"D Rimoldi","year":"2003","unstructured":"Rimoldi D, Salvi S, Lienard D, Lejeune FJ, Speiser D, Zografos L, Cerottini JC. Lack of BRAF mutations in uveal melanoma. Cancer Res. 2003;63:5712\u20135.","journal-title":"Cancer Res"},{"key":"1684_CR111","doi-asserted-by":"publisher","first-page":"4345","DOI":"10.1158\/1078-0432.CCR-11-3227","volume":"18","author":"JS Khalili","year":"2012","unstructured":"Khalili JS, Yu X, Wang J, Hayes BC, Davies MA, Lizee G, Esmaeli B, Woodman SE. Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent manner. Clin Cancer Res. 2012;18:4345\u201355. https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-3227.","journal-title":"Clin Cancer Res"},{"key":"1684_CR112","doi-asserted-by":"publisher","first-page":"3552","DOI":"10.1158\/1078-0432.CCR-11-3086","volume":"18","author":"G Ambrosini","year":"2012","unstructured":"Ambrosini G, Pratilas CA, Qin LX, Tadi M, Surriga O, Carvajal RD, Schwartz GK. Identification of unique MEK-dependent genes in GNAQ mutant uveal melanoma involved in cell growth, tumor cell invasion, and MEK resistance. Clin Cancer Res. 2012;18:3552\u201361. https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-3086.","journal-title":"Clin Cancer Res"},{"key":"1684_CR113","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.1001\/jama.2014.6096","volume":"311","author":"RD Carvajal","year":"2014","unstructured":"Carvajal RD, Sosman JA, Quevedo JF, Milhem MM, Joshua AM, Kudchadkar RR, Linette GP, Gajewski TF, Lutzky J, Lawson DH, et al. Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial. JAMA. 2014;311:2397\u2013405. https:\/\/doi.org\/10.1001\/jama.2014.6096.","journal-title":"JAMA"},{"key":"1684_CR114","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114009","volume":"202","author":"JJ Sacco","year":"2024","unstructured":"Sacco JJ, Jackson R, Corrie P, Danson S, Evans TRJ, Ochsenreither S, Kumar S, Goodman A, Larkin J, Karydis I, et al. A three-arm randomised phase II study of the MEK inhibitor selumetinib alone or in combination with paclitaxel in metastatic uveal melanoma. Eur J Cancer. 2024;202. https:\/\/doi.org\/10.1016\/j.ejca.2024.114009.","journal-title":"Eur J Cancer"},{"key":"1684_CR115","doi-asserted-by":"publisher","first-page":"5686","DOI":"10.1158\/1078-0432.CCR-18-3382","volume":"25","author":"F Faiao-Flores","year":"2019","unstructured":"Faiao-Flores F, Emmons MF, Durante MA, Kinose F, Saha B, Fang B, Koomen JM, Chellappan SP, Maria-Engler SS, Rix U, et al. HDAC Inhibition Enhances the In Vivo Efficacy of MEK Inhibitor Therapy in Uveal Melanoma. Clin Cancer Res. 2019;25:5686\u2013701. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-3382.","journal-title":"Clin Cancer Res"},{"key":"1684_CR116","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1158\/2767-9764.CRC-24-0036","volume":"4","author":"EI Buchbinder","year":"2024","unstructured":"Buchbinder EI, Cohen JV, Tarantino G, Lian CG, Liu D, Haq R, Hodi FS, Lawrence DP, Giobbie-Hurder A, Knoerzer D, et al. A Phase II Study of ERK Inhibition by Ulixertinib (BVD-523) in Metastatic Uveal Melanoma. Cancer Res Commun. 2024;4:1321\u20137. https:\/\/doi.org\/10.1158\/2767-9764.CRC-24-0036.","journal-title":"Cancer Res Commun"},{"key":"1684_CR117","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0029622","volume":"7","author":"X Wu","year":"2012","unstructured":"Wu X, Zhu M, Fletcher JA, Giobbie-Hurder A, Hodi FS. The protein kinase C inhibitor enzastaurin exhibits antitumor activity against uveal melanoma. PLoS ONE. 2012;7. https:\/\/doi.org\/10.1371\/journal.pone.0029622.","journal-title":"PLoS ONE"},{"key":"1684_CR118","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41389-024-00511-8","volume":"13","author":"JJ Park","year":"2024","unstructured":"Park JJ, Hamad SA, Stewart A, Carlino MS, Lim SY, Rizos H. PKC-independent PI3K signalling diminishes PKC inhibitor sensitivity in uveal melanoma. Oncogenesis. 2024;13:9. https:\/\/doi.org\/10.1038\/s41389-024-00511-8.","journal-title":"Oncogenesis"},{"key":"1684_CR119","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1038\/s41416-022-02133-6","volume":"128","author":"S Piperno-Neumann","year":"2023","unstructured":"Piperno-Neumann S, Carlino MS, Boni V, Loirat D, Speetjens FM, Park JJ, Calvo E, Carvajal RD, Nyakas M, Gonzalez-Maffe J, et al. A phase I trial of LXS196, a protein kinase C (PKC) inhibitor, for metastatic uveal melanoma. Br J Cancer. 2023;128:1040\u201351. https:\/\/doi.org\/10.1038\/s41416-022-02133-6.","journal-title":"Br J Cancer"},{"key":"1684_CR120","doi-asserted-by":"publisher","first-page":"S651","DOI":"10.1016\/j.annonc.2023.09.2215","volume":"34","author":"M McKean","year":"2023","unstructured":"McKean M, Chmielowski B, Butler MO, Carvajal R, Rodon J, Carlino M, Kim KB, Wise-draper T, Khan S, Salama AKS, et al. 1081O ctDNA reduction and clinical efficacy of the darovasertib + crizotinib (daro + crizo) combination in metastatic uveal melanoma (MUM). Ann Oncol. 2023;34:S651. https:\/\/doi.org\/10.1016\/j.annonc.2023.09.2215.","journal-title":"Ann Oncol"},{"key":"1684_CR121","doi-asserted-by":"publisher","unstructured":"Joshua, A.M.; O'day, R.; Glasson, W.; Sia, D.; McGrath, L.; Ameratunga, M.; Cosman, R.; Cherepanoff, S.; O'Quigley, M.; Beaupre, D.M.; et al. A phase 2 safety and efficacy study of neoadjuvant\/adjuvant darovasertib for localized ocular melanoma. Journal of Clinical Oncology 2024, 42, 9510\u20139510, https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.9510.","DOI":"10.1200\/JCO.2024.42.16_suppl.9510"},{"key":"1684_CR122","doi-asserted-by":"publisher","first-page":"9597","DOI":"10.1200\/JCO.2024.42.16_suppl.9597","volume":"42","author":"AMD Giacomo","year":"2024","unstructured":"Giacomo AMD, Simonelli M, Santangelo F, Amato G, Simonetti E, Graham J, Lahn MMF, Conza GD, Hammett T, Zorrilla R, et al. Roginolisib, an oral, highly selective and allosteric modulator of phosphoinositide 3-kinase inhibitor delta (PI3K\u03b4) in patients with uveal melanoma and advanced cancers. J Clin Oncol. 2024;42:9597\u20139597. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.9597.","journal-title":"J Clin Oncol"},{"key":"1684_CR123","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/j.ccr.2014.04.017","volume":"25","author":"FX Yu","year":"2014","unstructured":"Yu FX, Luo J, Mo JS, Liu G, Kim YC, Meng Z, Zhao L, Peyman G, Ouyang H, Jiang W, et al. Mutant Gq\/11 promote uveal melanoma tumorigenesis by activating YAP. Cancer Cell. 2014;25:822\u201330. https:\/\/doi.org\/10.1016\/j.ccr.2014.04.017.","journal-title":"Cancer Cell"},{"key":"1684_CR124","doi-asserted-by":"publisher","unstructured":"Feng, X.; Arang, N.; Rigiracciolo, D.C.; Lee, J.S.; Yeerna, H.; Wang, Z.; Lubrano, S.; Kishore, A.; Pachter, J.A.; Konig, G.M.; et al. A Platform of Synthetic Lethal Gene Interaction Networks Reveals that the GNAQ Uveal Melanoma Oncogene Controls the Hippo Pathway through FAK. Cancer Cell 2019, 35, 457\u2013472 e455, https:\/\/doi.org\/10.1016\/j.ccell.2019.01.009.","DOI":"10.1016\/j.ccell.2019.01.009"},{"key":"1684_CR125","doi-asserted-by":"publisher","first-page":"3190","DOI":"10.1158\/1078-0432.CCR-20-3363","volume":"27","author":"JS Paradis","year":"2021","unstructured":"Paradis JS, Acosta M, Saddawi-Konefka R, Kishore A, Gomes F, Arang N, Tiago M, Coma S, Lubrano S, Wu X, et al. Synthetic Lethal Screens Reveal Cotargeting FAK and MEK as a Multimodal Precision Therapy for GNAQ-Driven Uveal Melanoma. Clin Cancer Res. 2021;27:3190\u2013200. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-3363.","journal-title":"Clin Cancer Res"},{"key":"1684_CR126","doi-asserted-by":"publisher","unstructured":"Seedor, R.S.; Terai, M.; Majeed, A.; Tanaka, R.; Aplin, A.E.; Orloff, M.; Molinolo, A.A.; Gutkind, J.S.; Sato, T. Abstract CT260: A phase II trial of defactinib combined with avutometinib in patients with metastatic uveal melanoma. Cancer Research 2024, 84, CT260-CT260, https:\/\/doi.org\/10.1158\/1538-7445.Am2024-ct260.","DOI":"10.1158\/1538-7445.Am2024-ct260"},{"key":"1684_CR127","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/ncb2936","volume":"16","author":"G Sorrentino","year":"2014","unstructured":"Sorrentino G, Ruggeri N, Specchia V, Cordenonsi M, Mano M, Dupont S, Manfrin A, Ingallina E, Sommaggio R, Piazza S, et al. Metabolic control of YAP and TAZ by the mevalonate pathway. Nat Cell Biol. 2014;16:357\u201366. https:\/\/doi.org\/10.1038\/ncb2936.","journal-title":"Nat Cell Biol"},{"key":"1684_CR128","doi-asserted-by":"publisher","unstructured":"Amaro, A.A.; Gangemi, R.; Emionite, L.; Castagnola, P.; Filaci, G.; Jager, M.J.; Tanda, E.T.; Spagnolo, F.; Mascherini, M.; Pfeffer, U.; et al. Cerivastatin Synergizes with Trametinib and Enhances Its Efficacy in the Therapy of Uveal Melanoma. Cancers (Basel) 2023, 15, https:\/\/doi.org\/10.3390\/cancers15030886.","DOI":"10.3390\/cancers15030886"},{"key":"1684_CR129","doi-asserted-by":"publisher","unstructured":"Tanaka, R.; Terai, M.; Londin, E.; Sato, T. The Role of HGF\/MET Signaling in Metastatic Uveal Melanoma. Cancers (Basel) 2021, 13, https:\/\/doi.org\/10.3390\/cancers13215457.","DOI":"10.3390\/cancers13215457"},{"key":"1684_CR130","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.976837","volume":"12","author":"S Khan","year":"2022","unstructured":"Khan S, Lutzky J, Shoushtari AN, Jeter J, Marr B, Olencki TE, Cebulla CM, Abdel-Rahman M, Harbour JW, Sender N, et al. Adjuvant crizotinib in high-risk uveal melanoma following definitive therapy. Front Oncol. 2022;12. https:\/\/doi.org\/10.3389\/fonc.2022.976837.","journal-title":"Front Oncol"},{"key":"1684_CR131","doi-asserted-by":"publisher","unstructured":"Ohara, M.; Saito, K.; Kageyama, K.; Terai, M.; Cheng, H.; Aplin, A.E.; Sato, T. Dual Targeting of CDK4\/6 and cMET in Metastatic Uveal Melanoma. Cancers (Basel) 2021, 13, https:\/\/doi.org\/10.3390\/cancers13051104.","DOI":"10.3390\/cancers13051104"},{"key":"1684_CR132","doi-asserted-by":"publisher","first-page":"e930","DOI":"10.1634\/theoncologist.2018-0411","volume":"24","author":"AR He","year":"2019","unstructured":"He AR, Cohen RB, Denlinger CS, Sama A, Birnbaum A, Hwang J, Sato T, Lewis N, Mynderse M, Niland M, et al. First-in-Human Phase I Study of Merestinib, an Oral Multikinase Inhibitor, in Patients with Advanced Cancer. Oncologist. 2019;24:e930\u201342. https:\/\/doi.org\/10.1634\/theoncologist.2018-0411.","journal-title":"Oncologist"},{"key":"1684_CR133","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1038\/modpathol.2011.57","volume":"24","author":"ML Wallander","year":"2011","unstructured":"Wallander ML, Layfield LJ, Emerson LL, Mamalis N, Davis D, Tripp SR, Holden JA. KIT mutations in ocular melanoma: frequency and anatomic distribution. Mod Pathol. 2011;24:1031\u20135. https:\/\/doi.org\/10.1038\/modpathol.2011.57.","journal-title":"Mod Pathol"},{"key":"1684_CR134","doi-asserted-by":"publisher","first-page":"8523","DOI":"10.1200\/jco.2012.30.15_suppl.8523","volume":"30","author":"PD Nathan","year":"2012","unstructured":"Nathan PD, Marshall E, Smith CT, Bickerstaff M, Escriu C, Marples M, Damato B, Kalirai H, Coupland S. A Cancer Research UK two-stage multicenter phase II study of imatinib in the treatment of patients with c-kit positive metastatic uveal melanoma (ITEM). J Clin Oncol. 2012;30:8523\u20138523. https:\/\/doi.org\/10.1200\/jco.2012.30.15_suppl.8523.","journal-title":"J Clin Oncol"},{"key":"1684_CR135","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1158\/1078-0432.CCR-08-2243","volume":"15","author":"UB Hofmann","year":"2009","unstructured":"Hofmann UB, Kauczok-Vetter CS, Houben R, Becker JC. Overexpression of the KIT\/SCF in uveal melanoma does not translate into clinical efficacy of imatinib mesylate. Clin Cancer Res. 2009;15:324\u20139. https:\/\/doi.org\/10.1158\/1078-0432.CCR-08-2243.","journal-title":"Clin Cancer Res"},{"key":"1684_CR136","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s10637-008-9143-2","volume":"26","author":"N Penel","year":"2008","unstructured":"Penel N, Delcambre C, Durando X, Clisant S, Hebbar M, Negrier S, Fournier C, Isambert N, Mascarelli F, Mouriaux F. O-Mel-Inib: a Cancero-pole Nord-Ouest multicenter phase II trial of high-dose imatinib mesylate in metastatic uveal melanoma. Invest New Drugs. 2008;26:561\u20135. https:\/\/doi.org\/10.1007\/s10637-008-9143-2.","journal-title":"Invest New Drugs"},{"key":"1684_CR137","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1158\/1078-0432.CCR-11-0946","volume":"18","author":"S Landreville","year":"2012","unstructured":"Landreville S, Agapova OA, Matatall KA, Kneass ZT, Onken MD, Lee RS, Bowcock AM, Harbour JW. Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma. Clin Cancer Res. 2012;18:408\u201316. https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-0946.","journal-title":"Clin Cancer Res"},{"key":"1684_CR138","doi-asserted-by":"publisher","first-page":"5155","DOI":"10.1038\/s41467-021-25332-w","volume":"12","author":"L Ny","year":"2021","unstructured":"Ny L, Jespersen H, Karlsson J, Alsen S, Filges S, All-Eriksson C, Andersson B, Carneiro A, Helgadottir H, Levin M, et al. The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma. Nat Commun. 2021;12:5155. https:\/\/doi.org\/10.1038\/s41467-021-25332-w.","journal-title":"Nat Commun"},{"key":"1684_CR139","doi-asserted-by":"publisher","first-page":"9535","DOI":"10.1200\/JCO.2021.39.15_suppl.9535","volume":"39","author":"J Grimes","year":"2021","unstructured":"Grimes J, Shoushtari AN, Orloff M, Khan S, Chiuzan C, Hsiao SJ, McDonnell D, Marr BP, Carvajal RD. Clinical characteristics of SF3B1 mutant (mut) uveal melanoma (UM) and response to immune checkpoint inhibition (ICI). J Clin Oncol. 2021;39:9535\u20139535. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.9535.","journal-title":"J Clin Oncol"},{"key":"1684_CR140","doi-asserted-by":"publisher","unstructured":"Fong, J.Y.; Pignata, L.; Goy, P.A.; Kawabata, K.C.; Lee, S.C.; Koh, C.M.; Musiani, D.; Massignani, E.; Kotini, A.G.; Penson, A.; et al. Therapeutic Targeting of RNA Splicing Catalysis through Inhibition of Protein Arginine Methylation. Cancer Cell 2019, 36, 194\u2013209 e199, https:\/\/doi.org\/10.1016\/j.ccell.2019.07.003.","DOI":"10.1016\/j.ccell.2019.07.003"},{"key":"1684_CR141","doi-asserted-by":"crossref","unstructured":"Ito, K.; Thodima, V.; Carter, J.; Bhagwat, N.; Sivakumar, M.; Grego, A.; Rager, J.; Terai, M.; Sato, T.; Abdel-Wahab, O.; et al. Abstract 1137: PRMT5 inhibition regulates alternative splicing and DNA damage repair pathways in SF3B1 R625G expressing uveal melanoma cells; 2021; Volume 81, pp. 1137\u20131137.","DOI":"10.1158\/1538-7445.AM2021-1137"},{"key":"1684_CR142","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2021.728777","volume":"8","author":"KL Cheung","year":"2021","unstructured":"Cheung KL, Kim C, Zhou MM. The Functions of BET Proteins in Gene Transcription of Biology and Diseases. Front Mol Biosci. 2021;8. https:\/\/doi.org\/10.3389\/fmolb.2021.728777.","journal-title":"Front Mol Biosci"},{"key":"1684_CR143","doi-asserted-by":"publisher","first-page":"6264","DOI":"10.1158\/0008-5472.CAN-13-0122-T","volume":"73","author":"MF Segura","year":"2013","unstructured":"Segura MF, Fontanals-Cirera B, Gaziel-Sovran A, Guijarro MV, Hanniford D, Zhang G, Gonzalez-Gomez P, Morante M, Jubierre L, Zhang W, et al. BRD4 sustains melanoma proliferation and represents a new target for epigenetic therapy. Cancer Res. 2013;73:6264\u201376. https:\/\/doi.org\/10.1158\/0008-5472.CAN-13-0122-T.","journal-title":"Cancer Res"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-025-01684-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11912-025-01684-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-025-01684-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T02:20:56Z","timestamp":1754533256000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11912-025-01684-0"}},"subtitle":["How to treat Metastatic Uveal Melanoma in 2025"],"short-title":[],"issued":{"date-parts":[[2025,5,17]]},"references-count":143,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["1684"],"URL":"https:\/\/doi.org\/10.1007\/s11912-025-01684-0","relation":{},"ISSN":["1534-6269"],"issn-type":[{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,17]]},"assertion":[{"value":"28 April 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"H.G. has received honoraria by BMS, MSD, Pierre Fabre, Sanofi\/Regeneron and personal fees for advisory\/consultancy by BMS, MSD, Amgen, Pierre Fabre and Sanofi\/Regeneron, outside the submitted work; DCZ has received grants and personal fees by MSD, BMS, Roche, AstraZeneca, Ipsen, Amgen and Pierre Fabre, outside the submitted work;All other authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"HG has received grants and personal fees by Roche, BMS, MSD, Novartis and personal fees by Amgen and Pierre Fabre, outside the submitted work. Dimitrios C. Ziogas has received personal fees by Roche, BMS, MSD, ASTRAZENECA, GILEAD, IPSEN, Amgen and Pierre Fabre, outside the submitted work. All other authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interest"}}]}}